证券之星消息，截至2025年11月14日收盘，天臣医疗(688013)报收于56.0元，下跌2.12%，换手率 1.77%，成交量1.44万手，成交额8138.62万元。 | 指标 | 天臣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 45.45 乙元 | 116.39亿元 | 78 124 | | 净资产 | 6亿元 | 38.93亿元 | 115 124 | | 净利润 | 7194.58万元 | 2.12亿元 | 57 124 | | 市盈率(动) | 47.38 | 58.18 | 53 124 | | 市净率 | 7.58 | 4.14 | 113 124 | | 毛利率 | 63.22% | 51.22% | 43 124 | | 净利率 | 29.51% | 9.57% | 15 124 | | ROE | 12.52% | 0.15% | 9 124 | 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23万元，同比 ...

证券之星消息，截至2025年11月13日收盘，天臣医疗(688013)报收于57.21元，上涨1.72%，换手率 3.41%，成交量2.77万手，成交额1.6亿元。 | 指标 | 天臣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 46.43亿元 | 116.76亿元 | 77 124 | | 净资产 | 6亿元 | 38.93亿元 | 115 124 | | 净利润 | 7194.58万元 | 2.12亿元 | 57 124 | | 市盈率(动) | 48.4 | 60.24 | 53 124 | | 市净率 | 7.74 | 4.15 | 114 124 | | 毛利率 | 63.22% | 51.22% | 43 124 | | 净利率 | 29.51% | 9.57% | 15 124 | | ROE | 12.52% | 0.15% | 9 124 | 天臣医疗2025年三季报显示，前三季度公司主营收入2.44亿元，同比上升20.66%；归母净利润7194.58 万元，同比上升68.29%；扣非净利润6620.23万元，同比上升71. ...

长江商报奔腾新闻记者 沈右荣 股价大涨，天臣医疗（688013.SH）上调回购价格。 11月9日晚，天臣医疗公告称，拟将回购价格上限由不超过28.03元/股调整为不超过70.00元/股。 天臣医疗的本次回购股份计划始于2023年12月27日。当时，公司公告称，拟以集中竞价交易方式回购公 司股份，用于实施员工持股计划或股权激励，回购资金总额不低于1800万元，不超过3600万元，回购价 格不超过30元/股，回购期限自公司董事会审议通过回购方案之日起12个月内。 2024年7月9日，公司公告，增加股份回购金额并对回购股份的方案进行调整，回购资金总额调整为不低 于3600万元、不超过7200万元。 2024年中期权益分派实施后，公司对回购股份价格上限调整为不超过29.51元/股。 2024年12月25日，公司公告，将回购资金总额调整为不低于4600万元、不超过8000万元，将回购期限延 至2025年12月26日。 二级市场上，2025年初，天臣医疗股价为17.61元/股，11月10日盘中股价达到55.18元/股，年内涨幅超 过2倍。 天臣医疗主要从事高端外科手术吻合器研发创新和生产销售，2020年9月在科创板上市。 ...

Group 1 - The core viewpoint of the news is that Tianchen Medical has experienced significant stock price fluctuations and financial growth, with a notable increase in revenue and net profit year-on-year [1][2]. Group 2 - As of October 31, Tianchen Medical's stock price rose by 2.02% to 51.51 CNY per share, with a market capitalization of 4.18 billion CNY [1]. - The company has seen a year-to-date stock price increase of 219.28%, but has experienced a decline of 7.46% in the last five trading days and 13.05% in the last twenty days [1]. - Tianchen Medical's main business involves the research, innovation, and production of high-end surgical staplers, with 77.92% of revenue coming from non-powered products and 22.08% from powered products [1]. - As of September 30, the number of shareholders increased by 11.48% to 4,624, while the average circulating shares per person decreased by 10.29% to 17,550 shares [2]. - For the period from January to September 2025, Tianchen Medical achieved a revenue of 244 million CNY, representing a year-on-year growth of 20.66%, and a net profit of 71.95 million CNY, up 68.29% year-on-year [2]. - The company has distributed a total of 211 million CNY in dividends since its A-share listing, with 179 million CNY distributed over the past three years [2].

Group 1 - The core viewpoint of the news is that Tianchen Medical has shown significant stock performance, with a year-to-date increase of 251.77%, despite a recent decline of 6.85% over the last five trading days [1] - As of September 29, Tianchen Medical's stock price reached 58.50 CNY per share, with a market capitalization of 4.748 billion CNY [1] - The company specializes in the research, innovation, and production of high-end surgical staplers, with its main business revenue composition being 77.92% from non-powered products and 22.08% from powered products [1] Group 2 - For the first half of 2025, Tianchen Medical reported a revenue of 156 million CNY, representing a year-on-year growth of 17.66%, and a net profit attributable to shareholders of 48.2116 million CNY, which is a 67.10% increase compared to the previous year [2] - The number of shareholders decreased by 6.64% to 4,148, while the average circulating shares per person increased by 7.11% to 19,564 shares [2] - Since its A-share listing, Tianchen Medical has distributed a total of 171 million CNY in dividends, with 139 million CNY distributed over the past three years [2]

Core Viewpoint - Tianchen Medical (688013) has shown a positive performance with a closing price of 50.8 yuan, reflecting a 1.6% increase as of August 27, 2025, amidst varying capital flows [1][2]. Financial Performance - The company reported a main revenue of 156 million yuan for the first half of 2025, representing a year-on-year increase of 17.66% [4]. - The net profit attributable to shareholders was 48.21 million yuan, up 67.1% year-on-year [4]. - The second quarter of 2025 saw a single-quarter main revenue of 90.32 million yuan, a 24.56% increase year-on-year, and a net profit of 35.02 million yuan, which is a 100.15% increase year-on-year [4]. Capital Flow Analysis - On August 27, 2025, the net outflow of main funds was 3.56 million yuan, accounting for 1.62% of the total transaction amount, while retail funds saw a net outflow of 495,300 yuan [1]. - Over the past five days, the financing balance increased to 128 million yuan, with a net financing purchase of 7.23 million yuan on August 27 [2]. Industry Comparison - Tianchen Medical's total market value is 4.123 billion yuan, significantly lower than the industry average of 12.081 billion yuan, ranking 89th out of 123 in the medical device industry [4]. - The company's net profit margin stands at 30.87%, which is considerably higher than the industry average of 11.01%, ranking 14th in the industry [4]. - The company's gross margin is 63.03%, surpassing the industry average of 51.64%, ranking 44th in the industry [4].

Core Insights - Tianchen Medical (688013) reported a closing price of 50.0 yuan on August 26, 2025, with a 10.5% increase, and a trading volume of 4.55 million shares, amounting to a total transaction value of 219 million yuan [1][2] Financial Performance - The company achieved a main revenue of 156 million yuan in the first half of 2025, representing a year-on-year increase of 17.66% - The net profit attributable to shareholders was 48.21 million yuan, up 67.1% year-on-year - The net profit after deducting non-recurring gains and losses was 44.29 million yuan, reflecting a 71.48% increase year-on-year - In Q2 2025, the company reported a single-quarter main revenue of 90.32 million yuan, a 24.56% increase year-on-year, and a net profit of 35.02 million yuan, which is a 100.15% increase year-on-year [4] Market Position - Tianchen Medical's total market capitalization is 4.058 billion yuan, with a net asset value of 574 million yuan - The company ranks 94th in total market value and 115th in net assets within the medical device industry - The company's price-to-earnings ratio (P/E) is 42.08, which is lower than the industry average of 65.87, ranking 49th in the industry - The gross profit margin stands at 63.03%, significantly higher than the industry average of 51.29%, ranking 43rd in the industry [3][4] Capital Flow - On August 26, 2025, the net inflow of main funds was 18.12 million yuan, accounting for 8.29% of the total transaction value - Retail investors experienced a net outflow of 16.66 million yuan, representing 7.62% of the total transaction value - The financing balance on the same day was 121 million yuan, with a net financing purchase of 7.12 million yuan [1][2]

Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance with a closing price of 41.25 yuan on August 21, 2025, reflecting a 3.44% increase, despite a net outflow of main funds [1][2]. Group 1: Stock Performance and Trading Data - On August 21, 2025, Tianchen Medical's stock price increased by 3.44% with a trading volume of 22,200 hands and a total transaction amount of 89.30 million yuan [1]. - The main funds experienced a net outflow of 10.25 million yuan, accounting for 11.47% of the total transaction amount, while retail investors saw a net inflow of 5.84 million yuan, representing 6.54% of the total [1][2]. - Over the past five days, the stock has fluctuated, with the highest closing price being 41.25 yuan and the lowest at 39.04 yuan [2]. Group 2: Financing and Margin Trading Data - As of August 21, 2025, the financing balance for Tianchen Medical was 106 million yuan, with a net financing purchase of 1.42 million yuan [3]. - The company had no short-selling activity, with a margin trading balance remaining at 106 million yuan [3]. Group 3: Company Financials and Industry Comparison - Tianchen Medical reported a main revenue of 65.84 million yuan for Q1 2025, a year-on-year increase of 9.34%, and a net profit of 13.19 million yuan, up 16.16% year-on-year [5]. - The company has a total market value of 3.348 billion yuan, which is significantly lower than the industry average of 12.244 billion yuan [5]. - Key financial metrics include a price-to-earnings ratio of 63.47, a price-to-book ratio of 6.3, and a gross margin of 58.46%, all of which indicate a competitive position within the medical device industry [5].

Core Insights - Tianchen Medical (688013) closed at 39.95 yuan on August 18, 2025, with a 2.33% increase and a trading volume of 25,600 hands, resulting in a transaction amount of 102 million yuan [1][2]. Fund Flow Analysis - On August 18, 2025, the net outflow of main funds was 7.36 million yuan, accounting for 7.21% of the total transaction amount, while retail funds saw a net inflow of 0.40 million yuan, representing 0.4% of the total transaction amount [1][2]. - Over the past five days, the fund flow data shows fluctuations, with notable net inflows and outflows from main and retail funds on different days [2]. Company Performance Metrics - Tianchen Medical's total market value is 3.242 billion yuan, with a net asset of 572 million yuan and a net profit of 13.19 million yuan [3]. - The company reported a revenue of 65.85 million yuan in Q1 2025, reflecting a year-on-year increase of 9.34%, and a net profit increase of 16.16% [3]. - Key financial ratios include a price-to-earnings ratio of 61.47, a price-to-book ratio of 6.1, a gross margin of 58.46%, and a net margin of 20.03% [3].

Core Viewpoint - Tianchen Medical (688013) experienced a decline in stock price, closing at 37.88 yuan on August 6, 2025, down 4.51% from the previous day, indicating a negative trend in investor sentiment and market performance [1]. Group 1: Stock Performance and Trading Data - On August 6, 2025, the stock had a turnover rate of 7.1%, with a trading volume of 57,600 hands and a total transaction value of 215 million yuan [1]. - The net outflow of main funds was 15.8863 million yuan, accounting for 7.41% of the total transaction value, while retail investors saw a net inflow of 5.1648 million yuan, representing 2.41% of the total [1]. - Over the past five days, the stock has shown fluctuating performance, with a notable drop on August 6, following a slight increase on August 4 [1][2]. Group 2: Financing and Margin Trading - As of August 6, 2025, the financing balance was 102 million yuan, with a net financing purchase of 12.9725 million yuan, indicating positive investor interest in leveraging positions [2]. - The margin trading data shows no short selling activity, with a total margin trading balance of 102 million yuan [2]. Group 3: Company Financials and Industry Comparison - Tianchen Medical reported a total market capitalization of 3.074 billion yuan, significantly lower than the industry average of 11.525 billion yuan, ranking 101 out of 123 in the medical device sector [4]. - The company’s net profit for the first quarter of 2025 was 13.1867 million yuan, reflecting a year-on-year increase of 16.16%, while its main revenue was 65.8461 million yuan, up 9.34% year-on-year [4]. - The company has a gross margin of 58.46%, which is higher than the industry average of 51.31%, indicating strong operational efficiency [4].